The IDIAP Jordi Gol
Who we are
Organization
Directory
Quality Certification
Strategic plan
Annual reports
Work with us
HRS4R
Transparency
Research
Territorial Support Units (USR)
Call Ajuts ICS/IDIAP 2025
Research Areas
Publications
Projects
Featured research projects
European Projects
CEIm
CEIM presentation
How to Submit the Documentation to the CEIM
Rates of The CEI
CEI meeting calendar
Regulations and links of interest CEI
Platforms
AGICAP
Sidiap Database
Clinical Trial
Services
Grants to Finance Research
Platforms Questionnaires
Real World Lab
Tools-Help
Scientific Tools
Management Tools
IDIAP Management Tools
Innovation
News
Link GIR
Acces GIR
Login
Català
Castellano
English
The IDIAP Jordi Gol
Who we are
Organization
Directory
Quality Certification
Strategic plan
Annual reports
Work with us
HRS4R
Transparency
Research
Territorial Support Units (USR)
Call Ajuts ICS/IDIAP 2025
Research Areas
Publications
Projects
Featured research projects
European Projects
CEIm
CEIM presentation
How to Submit the Documentation to the CEIM
Rates of The CEI
CEI meeting calendar
Regulations and links of interest CEI
Platforms
AGICAP
Sidiap Database
Clinical Trial
Services
Grants to Finance Research
Platforms Questionnaires
Real World Lab
Tools-Help
Scientific Tools
Management Tools
IDIAP Management Tools
Innovation
News
Link GIR
Search
Most popular
COL·LABORA
Menu
English
Català
Español
Home
Àrees Recerca
DIABETES
Diabetis-de-Reus-Tarragona
Diabetis-de-Reus-Tarragona
Diabetis-de-Reus-Tarragona
Group leader
Juan José Cabré Vila
jcabre.tgn.ics@gencat.cat
Presentation
Team
Publications
Projects
News
Presentation
Team
Publications
Projects
News
Projects
Group projects
Estudio español multicéntrico, paralelo, doble ciego, aleatorizado y controlado con placebo, para prevenir o retrasar el desarrollo de diabetes tipo 2 en sujetos con alteración de la homeostasis glucídica tratados con acarbosa en atención primaria (PREDIA
Principal investigators:
Bernardo Costa Pinel
Code:
5A00/008
Start year:
2000
14 – SAS30024 (Glaxo)
Principal investigators:
Francisco Martín Luján
Code:
5A02/014
Start year:
2002
07 – CL2-21403-018 ESP (Laboratorios Servier)
Principal investigators:
Bernardo Costa Pinel
Code:
5A03/007
Start year:
2003
Extensión de 52 semanas de duración del estudio multicéntrico, aleatorizado, doble ciego controlado con fármaco activo para evaluar los efectos de 52 semanas de tratamiento con 50 mg de LAF237 bid frente a metformina hasta 1000mg bid en pacientes naive c
Principal investigators:
Bernardo Costa Pinel
Code:
5A04/038
Start year:
2004
A single-centre, open-label study testing the safety and performance of the Glyconics-SX System in assessment of glycated nail keratin, compared with standardised glycated haemoglobin (HbA1c) assay, in individuals with or without type 2 diabetes in Catalonia (Spain).
Principal investigators:
Francesc Xavier Cos Claramunt
Code:
4R22/137
Start year:
2022
Funders:
GLYCONICS LTD
Anterior
1
…
7
8
9
10
Següent
Board of Trustees
Collaborators
Accreditations